{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:28:11Z","timestamp":1781882891991,"version":"3.54.5"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Anhui Natural Science Foundation","award":["2023AH040086"],"award-info":[{"award-number":["2023AH040086"]}]},{"name":"Anhui Natural Science Foundation","award":["2023AH040086"],"award-info":[{"award-number":["2023AH040086"]}]},{"name":"Anhui Natural Science Foundation","award":["2023AH040086"],"award-info":[{"award-number":["2023AH040086"]}]},{"name":"Anhui Natural Science Foundation","award":["2023AH040086"],"award-info":[{"award-number":["2023AH040086"]}]},{"name":"Anhui Natural Science Foundation","award":["2023AH040086"],"award-info":[{"award-number":["2023AH040086"]}]},{"name":"Anhui Natural Science Foundation","award":["2023AH040086"],"award-info":[{"award-number":["2023AH040086"]}]},{"name":"Key Laboratory of Philosophy and Social of Anhui Province on Adolescent Mental Health and Intelligence Intervention","award":["SYS2023B08"],"award-info":[{"award-number":["SYS2023B08"]}]},{"name":"Key Laboratory of Philosophy and Social of Anhui Province on Adolescent Mental Health and Intelligence Intervention","award":["SYS2023B08"],"award-info":[{"award-number":["SYS2023B08"]}]},{"name":"Key Laboratory of Philosophy and Social of Anhui Province on Adolescent Mental Health and Intelligence Intervention","award":["SYS2023B08"],"award-info":[{"award-number":["SYS2023B08"]}]},{"name":"Key Laboratory of Philosophy and Social of Anhui Province on Adolescent Mental Health and Intelligence Intervention","award":["SYS2023B08"],"award-info":[{"award-number":["SYS2023B08"]}]},{"name":"Key Laboratory of Philosophy and Social of Anhui Province on Adolescent Mental Health and Intelligence Intervention","award":["SYS2023B08"],"award-info":[{"award-number":["SYS2023B08"]}]},{"name":"Key Laboratory of Philosophy and Social of Anhui Province on Adolescent Mental Health and Intelligence Intervention","award":["SYS2023B08"],"award-info":[{"award-number":["SYS2023B08"]}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["X202310366080"],"award-info":[{"award-number":["X202310366080"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["X202310366080"],"award-info":[{"award-number":["X202310366080"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["X202310366080"],"award-info":[{"award-number":["X202310366080"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["X202310366080"],"award-info":[{"award-number":["X202310366080"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["X202310366080"],"award-info":[{"award-number":["X202310366080"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["X202310366080"],"award-info":[{"award-number":["X202310366080"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00210-024-03258-6","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T10:03:08Z","timestamp":1719914588000},"page":"9227-9241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research"],"prefix":"10.1007","volume":"397","author":[{"given":"Wenhao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhuo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anran","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"3258_CR1","doi-asserted-by":"publisher","first-page":"150923","DOI":"10.1016\/j.soncn.2019.08.002","volume":"35","author":"M Abbott","year":"2019","unstructured":"Abbott M, Ustoyev Y (2019) Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs 35:150923. https:\/\/doi.org\/10.1016\/j.soncn.2019.08.002","journal-title":"Semin Oncol Nurs"},{"key":"3258_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.15537\/smj.2021.42.3.20210660","volume":"42","author":"AF Alfouzan","year":"2021","unstructured":"Alfouzan AF (2021) Radiation therapy in head and neck cancer. Saudi Med J 42:247\u2013254. https:\/\/doi.org\/10.15537\/smj.2021.42.3.20210660","journal-title":"Saudi Med J"},{"key":"3258_CR3","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F (2022) A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 28:2145\u20132154. https:\/\/doi.org\/10.1038\/s41591-022-01969-y","journal-title":"Nat Med"},{"key":"3258_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH (2023) CAR T therapy beyond cancer: the evolution of a living drug. Nature 619:707\u2013715. https:\/\/doi.org\/10.1038\/s41586-023-06243-w","journal-title":"Nature"},{"key":"3258_CR5","doi-asserted-by":"publisher","unstructured":"Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S (2019) Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci 20. https:\/\/doi.org\/10.3390\/ijms20061283","DOI":"10.3390\/ijms20061283"},{"key":"3258_CR6","doi-asserted-by":"publisher","unstructured":"Benoit A, Boies MHB, D\u00e9ry N, Garcia LM, Simard M, Poirier M, Delage R, Lortal Canguilhem B, Doyle C, Larouche JF, Couture F, Lemieux C (2023) CAR T-cells for the treatment of refractory or relapsed large B-cell lymphoma: a single-center retrospective Canadian study. Clin Lymphoma Myeloma Leuk 23:203\u2013210. https:\/\/doi.org\/10.1016\/j.clml.2022.12.015","DOI":"10.1016\/j.clml.2022.12.015"},{"key":"3258_CR7","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.ccell.2023.11.004","volume":"41","author":"E Bergaggio","year":"2023","unstructured":"Bergaggio E, Tai WT, Aroldi A, Mecca C, Landoni E, N\u00fcesch M, Mota I, Metovic J, Molinaro L, Ma L, Alvarado D, Ambrogio C, Voena C, Blasco RB, Li T, Klein D, Irvine DJ, Papotti M, Savoldo B, Dotti G, Chiarle R (2023) ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell 41:2100-2116.e2110. https:\/\/doi.org\/10.1016\/j.ccell.2023.11.004","journal-title":"Cancer Cell"},{"key":"3258_CR8","doi-asserted-by":"publisher","unstructured":"Braden AM, Stankowski RV, Engel JM, Onitilo AA (2014) Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence. Curr Pharm Des 20:4879\u20134898. https:\/\/doi.org\/10.2174\/1381612819666131125145517","DOI":"10.2174\/1381612819666131125145517"},{"key":"3258_CR9","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra138","journal-title":"Sci Transl Med"},{"key":"3258_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1759-7714.12916","volume":"10","author":"M Cao","year":"2019","unstructured":"Cao M, Chen W (2019) Epidemiology of lung cancer in China. Thorac Cancer 10:3\u20137. https:\/\/doi.org\/10.1111\/1759-7714.12916","journal-title":"Thorac Cancer"},{"key":"3258_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3163\/1536-5050.103.4.013","volume":"103","author":"ID Cooper","year":"2015","unstructured":"Cooper ID (2015) Bibliometrics basics. J Med Libr Assoc 103:217\u2013218. https:\/\/doi.org\/10.3163\/1536-5050.103.4.013","journal-title":"J Med Libr Assoc"},{"key":"3258_CR12","doi-asserted-by":"publisher","first-page":"103404","DOI":"10.1016\/j.retram.2023.103404","volume":"71","author":"A Das","year":"2023","unstructured":"Das A, Ghose A, Naicker K, Sanchez E, Chargari C, Rassy E, Boussios S (2023) Advances in adoptive T-cell therapy for metastatic melanoma. Curr Res Transl Med 71:103404. https:\/\/doi.org\/10.1016\/j.retram.2023.103404","journal-title":"Curr Res Transl Med"},{"issue":"7","key":"3258_CR13","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.3390\/ijms24076300","volume":"24","author":"RC De Marco","year":"2023","unstructured":"De Marco RC, Monzo HJ, Ojala PM (2023) CAR T cell therapy: a versatile living drug. Int J Mol Sci 24(7):6300. https:\/\/doi.org\/10.3390\/ijms24076300","journal-title":"Int J Mol Sci"},{"key":"3258_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L (2020) \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 19:185\u2013199. https:\/\/doi.org\/10.1038\/s41573-019-0051-2","journal-title":"Nat Rev Drug Discov"},{"key":"3258_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.21037\/tcr-21-1962","volume":"11","author":"H Ding","year":"2022","unstructured":"Ding H, Zhang X, Gang D, He X, Jiang S (2022) A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021. Transl Cancer Res 11:772\u2013783. https:\/\/doi.org\/10.21037\/tcr-21-1962","journal-title":"Transl Cancer Res"},{"issue":"18","key":"3258_CR16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2217\/imt-2020-0181","volume":"12","author":"N El-Khazragy","year":"2020","unstructured":"El-Khazragy N, Ghozy S, Emad P, Mourad M, Razza D, Farouk YK, Mohamed NA, Ahmed MK, Youssef T, Bahnasawy YM, Elmasery S (2020) Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. Immunotherapy 12(18):1341\u20131357. https:\/\/doi.org\/10.2217\/imt-2020-0181","journal-title":"Immunotherapy"},{"key":"3258_CR17","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","volume":"94","author":"S Feins","year":"2019","unstructured":"Feins S, Kong W, Williams EF, Milone MC, Fraietta JA (2019) An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol 94:S3-s9. https:\/\/doi.org\/10.1002\/ajh.25418","journal-title":"Am J Hematol"},{"key":"3258_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M (2023) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol 20:49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3","journal-title":"Nat Rev Clin Oncol"},{"key":"3258_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O\u2019Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563\u2013571. https:\/\/doi.org\/10.1038\/s41591-018-0010-1","journal-title":"Nat Med"},{"key":"3258_CR20","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","volume":"7","author":"T Glisovic-Aplenc","year":"2023","unstructured":"Glisovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova O, Shen F, Nunez-Cruz S, Vincent TL, Miao F, Milone MC, June CH, Teachey DT, Tasian SK, Aplenc R, Gill S (2023) CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv 7:4418\u20134430. https:\/\/doi.org\/10.1182\/bloodadvances.2022007059","journal-title":"Blood Adv"},{"key":"3258_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh M, Mansilla-Soto J, Rivi\u00e8re I, Sadelain M (2023) Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov 13:829\u2013843. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0101","journal-title":"Cancer Discov"},{"key":"3258_CR22","doi-asserted-by":"publisher","unstructured":"Haslauer T, Greil R, Zaborsky N, Geisberger R (2021) CAR T-cell therapy in hematological malignancies. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22168996","DOI":"10.3390\/ijms22168996"},{"key":"3258_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez KJ, Allen BM, Spitzer MH (2021) Systemic immunity in cancer. Nat Rev Cancer 21:345\u2013359. https:\/\/doi.org\/10.1038\/s41568-021-00347-z","journal-title":"Nat Rev Cancer"},{"key":"3258_CR24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1634\/theoncologist.2013-0457","volume":"19","author":"D Hui","year":"2014","unstructured":"Hui D, dos Santos R, Chisholm G, Bansal S, Silva TB, Kilgore K, Crovador CS, Yu X, Swartz MD, Perez-Cruz PE, Leite Rde A, Nascimento MS, Reddy S, Seriaco F, Yennu S, Paiva CE, Dev R, Hall S, Fajardo J, Bruera E (2014) Clinical signs of impending death in cancer patients. Oncologist 19:681\u2013687. https:\/\/doi.org\/10.1634\/theoncologist.2013-0457","journal-title":"Oncologist"},{"key":"3258_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.23736\/S2724-5691.23.09854-4","volume":"78","author":"A Kanani","year":"2023","unstructured":"Kanani A, Veen T, Alexeeva M, Lea D, S\u00f8reide K (2023) Neoadjuvant immunotherapy in colorectal cancer beyond immune checkpoint inhibitors: emerging from bench to bedside. Minerva Surg 78:385\u2013400. https:\/\/doi.org\/10.23736\/S2724-5691.23.09854-4","journal-title":"Minerva Surg"},{"key":"3258_CR26","doi-asserted-by":"publisher","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH (2016) Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44:712. https:\/\/doi.org\/10.1016\/j.immuni.2016.02.023","DOI":"10.1016\/j.immuni.2016.02.023"},{"key":"3258_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/14712598.2018.1384810","volume":"18","author":"E Landoni","year":"2018","unstructured":"Landoni E, Savoldo B (2018) Treating hematological malignancies with cell therapy: where are we now? Expert Opin Biol Ther 18:65\u201375. https:\/\/doi.org\/10.1080\/14712598.2018.1384810","journal-title":"Expert Opin Biol Ther"},{"key":"3258_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"3258_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2016","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C (2016) Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev 4:92\u2013101. https:\/\/doi.org\/10.1016\/j.omtm.2016.12.006","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3258_CR30","doi-asserted-by":"publisher","first-page":"114838","DOI":"10.1016\/j.ejmech.2022.114838","volume":"244","author":"D Li","year":"2022","unstructured":"Li D, Yu D, Li Y, Yang R (2022) A bibliometric analysis of PROTAC from 2001 to 2021. Eur J Med Chem 244:114838. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114838","journal-title":"Eur J Med Chem"},{"key":"3258_CR31","doi-asserted-by":"publisher","first-page":"2291900","DOI":"10.1080\/21645515.2023.2291900","volume":"19","author":"H Li","year":"2023","unstructured":"Li H, Huang Q, Zhang Y (2023a) A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023. Hum Vaccin Immunother 19:2291900. https:\/\/doi.org\/10.1080\/21645515.2023.2291900","journal-title":"Hum Vaccin Immunother"},{"key":"3258_CR32","doi-asserted-by":"publisher","first-page":"1142703","DOI":"10.3389\/fonc.2023.1142703","volume":"13","author":"X Li","year":"2023","unstructured":"Li X, Zhang W, Yuan S, Mao Q, Zhang C, Cai R, Lin H, Wang X (2023b) Publication trends and hotspots of colorectal adenoma during 2002\u20132022: a bibliometric and visualized analysis. Front Oncol 13:1142703. https:\/\/doi.org\/10.3389\/fonc.2023.1142703","journal-title":"Front Oncol"},{"key":"3258_CR33","doi-asserted-by":"publisher","first-page":"113932","DOI":"10.1016\/j.bios.2021.113932","volume":"201","author":"X Liu","year":"2022","unstructured":"Liu X, Zhao S, Tan L, Tan Y, Wang Y, Ye Z, Hou C, Xu Y, Liu S, Wang G (2022a) Frontier and hot topics in electrochemiluminescence sensing technology based on CiteSpace bibliometric analysis. Biosens Bioelectron 201:113932. https:\/\/doi.org\/10.1016\/j.bios.2021.113932","journal-title":"Biosens Bioelectron"},{"key":"3258_CR34","doi-asserted-by":"publisher","first-page":"925924","DOI":"10.3389\/fonc.2022.925924","volume":"12","author":"G Liu","year":"2022","unstructured":"Liu G, Zhao J, Tian G, Li S, Lu Y (2022b) Visualizing knowledge evolution trends and research hotspots of artificial intelligence in colorectal cancer: a bibliometric analysis. Front Oncol 12:925924. https:\/\/doi.org\/10.3389\/fonc.2022.925924","journal-title":"Front Oncol"},{"key":"3258_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20:31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"key":"3258_CR36","doi-asserted-by":"publisher","first-page":"1199145","DOI":"10.3389\/fimmu.2023.1199145","volume":"14","author":"Z Lv","year":"2023","unstructured":"Lv Z, Luo F, Chu Y (2023) Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy. Front Immunol 14:1199145. https:\/\/doi.org\/10.3389\/fimmu.2023.1199145","journal-title":"Front Immunol"},{"key":"3258_CR37","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.20892\/j.issn.2095-3941.2022.0231","volume":"19","author":"C Maomao","year":"2022","unstructured":"Maomao C, He L, Dianqin S, Siyi H, Xinxin Y, Fan Y, Shaoli Z, Changfa X, Lin L, Ji P, Wanqing C (2022) Current cancer burden in China: epidemiology, etiology, and prevention. Cancer Biol Med 19:1121\u20131138. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2022.0231","journal-title":"Cancer Biol Med"},{"key":"3258_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK (2019) CAR T Cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 10:128. https:\/\/doi.org\/10.3389\/fimmu.2019.00128","journal-title":"Front Immunol"},{"key":"3258_CR39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMx160005","volume":"374","author":"SL Maude","year":"2016","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA (2016) Chimeric antigen receptor-modified t cells in chronic lymphoid leukemia; chimeric antigen receptor-modified T cells for acute lymphoid leukemia; chimeric antigen receptor t cells for sustained remissions in leukemia. N Engl J Med 374:998. https:\/\/doi.org\/10.1056\/NEJMx160005","journal-title":"N Engl J Med"},{"key":"3258_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378:439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"key":"3258_CR41","doi-asserted-by":"publisher","first-page":"840956","DOI":"10.3389\/fimmu.2022.840956","volume":"13","author":"L Miao","year":"2022","unstructured":"Miao L, Zhang J, Zhang Z, Wang S, Tang F, Teng M, Li Y (2022) a bibliometric and knowledge-map analysis of CAR-T cells from 2009 to 2021. Front Immunol 13:840956. https:\/\/doi.org\/10.3389\/fimmu.2022.840956","journal-title":"Front Immunol"},{"key":"3258_CR42","doi-asserted-by":"publisher","first-page":"2338984","DOI":"10.1080\/21645515.2024.2338984","volume":"20","author":"L Miao","year":"2024","unstructured":"Miao L, Zhang J, Xu W, Qian Q, Zhang G, Yuan Q, Lv Y, Zhang H, Shen C, Wang W (2024) Global research trends in CAR-T cell therapy for solid tumors: a comprehensive visualization and bibliometric study (2012\u20132023). Hum Vaccin Immunother 20:2338984. https:\/\/doi.org\/10.1080\/21645515.2024.2338984","journal-title":"Hum Vaccin Immunother"},{"key":"3258_CR43","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"3258_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40037-021-00695-4","volume":"11","author":"A Ninkov","year":"2022","unstructured":"Ninkov A, Frank JR, Maggio LA (2022) Bibliometrics: methods for studying academic publishing. Perspect Med Educ 11:173\u2013176. https:\/\/doi.org\/10.1007\/s40037-021-00695-4","journal-title":"Perspect Med Educ"},{"key":"3258_CR45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12967-022-03285-y","volume":"20","author":"ST Nobari","year":"2022","unstructured":"Nobari ST, Nojadeh JN, Talebi M (2022) B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages. J Transl Med 20:82. https:\/\/doi.org\/10.1186\/s12967-022-03285-y","journal-title":"J Transl Med"},{"key":"3258_CR46","doi-asserted-by":"publisher","first-page":"e220126","DOI":"10.1148\/rycan.220126","volume":"5","author":"N Onishi","year":"2023","unstructured":"Onishi N, Bareng TJ, Gibbs J, Li W, Price ER, Joe BN, Kornak J, Esserman LJ, Newitt DC, Hylton NM (2023) Effect of longitudinal variation in tumor volume estimation for MRI-guided personalization of breast cancer neoadjuvant treatment. Radiol Imaging Cancer 5:e220126. https:\/\/doi.org\/10.1148\/rycan.220126","journal-title":"Radiol Imaging Cancer"},{"issue":"47","key":"3258_CR47","first-page":"277","volume":"9","author":"JH Park","year":"2010","unstructured":"Park JH, Brentjens RJ (2010) Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 9(47):277\u2013288","journal-title":"Discov Med"},{"key":"3258_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jconrel.2022.10.023","volume":"352","author":"Z Pei","year":"2022","unstructured":"Pei Z, Chen S, Ding L, Liu J, Cui X, Li F, Qiu F (2022) Current perspectives and trend of nanomedicine in cancer: a review and bibliometric analysis. J Control Release 352:211\u2013241. https:\/\/doi.org\/10.1016\/j.jconrel.2022.10.023","journal-title":"J Control Release"},{"key":"3258_CR49","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1007\/s00262-020-02630-8","volume":"69","author":"S Pouliliou","year":"2020","unstructured":"Pouliliou S, Nikolaidis C, Drosatos G (2020) Current trends in cancer immunotherapy: a literature-mining analysis. Cancer Immunol Immunother 69:2425\u20132439. https:\/\/doi.org\/10.1007\/s00262-020-02630-8","journal-title":"Cancer Immunol Immunother"},{"key":"3258_CR50","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380:1726\u20131737. https:\/\/doi.org\/10.1056\/NEJMoa1817226","journal-title":"N Engl J Med"},{"key":"3258_CR51","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1615\/critrevimmunol.v27.i5.20","volume":"27","author":"WL Redmond","year":"2007","unstructured":"Redmond WL, Weinberg AD (2007) Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol 27:415\u2013436. https:\/\/doi.org\/10.1615\/critrevimmunol.v27.i5.20","journal-title":"Crit Rev Immunol"},{"key":"3258_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-57362-1_1","volume":"217","author":"JT Schiller","year":"2021","unstructured":"Schiller JT, Lowy DR (2021) An introduction to virus infections and human cancer. Recent Results Cancer Res 217:1\u201311. https:\/\/doi.org\/10.1007\/978-3-030-57362-1_1","journal-title":"Recent Results Cancer Res"},{"key":"3258_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, J\u00e4ger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak \u00d6, Salles G, Maziarz RT (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"3258_CR54","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1590\/1806-9282.20221255","volume":"69","author":"ES \u015eeber","year":"1992","unstructured":"\u015eeber ES, \u0130riagac Y, \u00c7avdar E, Karaboyun K, Avc\u0131 O, Yolcu A, G\u00fcrdal S (1992) \u00d6znur M (2023) A logarithmic model for hormone receptor-positive and breast cancer patients treated with neoadjuvant chemotherapy. Rev Assoc Med Bras 69:434\u2013439. https:\/\/doi.org\/10.1590\/1806-9282.20221255","journal-title":"Rev Assoc Med Bras"},{"key":"3258_CR55","doi-asserted-by":"publisher","first-page":"800499","DOI":"10.3389\/fonc.2022.800499","volume":"12","author":"Y Shi","year":"2022","unstructured":"Shi Y, Luo J, Wang X, Zhang Y, Zhu H, Su D, Yu W, Tian J (2022) Emerging trends on the correlation between neurotransmitters and tumor progression in the last 20 years: a bibliometric analysis via CiteSpace. Front Oncol 12:800499. https:\/\/doi.org\/10.3389\/fonc.2022.800499","journal-title":"Front Oncol"},{"key":"3258_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11:69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"key":"3258_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2023.07.001","author":"LJ Talbot","year":"2023","unstructured":"Talbot LJ, Lautz TB, Aldrink JH, Ehrlich PF, Dasgupta R, Mattei P, Tracy ET, Glick RD, Grant CM, Brown EG, Christison-Lagay ER, Rodeberg DA (2023) Implications of immunotherapy for pediatric malignancies: a summary from the APSA cancer committee. J Pediatr Surg. https:\/\/doi.org\/10.1016\/j.jpedsurg.2023.07.001","journal-title":"J Pediatr Surg"},{"issue":"21","key":"3258_CR58","doi-asserted-by":"publisher","first-page":"15688","DOI":"10.3390\/ijms242115688","volume":"24","author":"AC Uscanga-Palomeque","year":"2023","unstructured":"Uscanga-Palomeque AC, Ch\u00e1vez-Escamilla AK, Alvizo-B\u00e1ez CA, Saavedra-Alonso S, Terrazas-Armend\u00e1riz LD, Tamez-Guerra RS, Rodr\u00edguez-Padilla C, Alcocer-Gonz\u00e1lez JM (2023) CAR-T cell therapy: from the shop to cancer therapy. Int J Mol Sci 24(21):15688. https:\/\/doi.org\/10.3390\/ijms242115688","journal-title":"Int J Mol Sci"},{"key":"3258_CR59","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jviscsurg.2021.11.011","volume":"158","author":"R Villet","year":"2021","unstructured":"Villet R (2021) The surgery and surgeons of tomorrow in the treatment of cancer. J Visc Surg 158:459\u2013461. https:\/\/doi.org\/10.1016\/j.jviscsurg.2021.11.011","journal-title":"J Visc Surg"},{"key":"3258_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41568-022-00529-3","volume":"23","author":"A Wahida","year":"2023","unstructured":"Wahida A, Buschhorn L, Fr\u00f6hling S, Jost PJ, Schneeweiss A, Lichter P, Kurzrock R (2023) The coming decade in precision oncology: six riddles. Nat Rev Cancer 23:43\u201354. https:\/\/doi.org\/10.1038\/s41568-022-00529-3","journal-title":"Nat Rev Cancer"},{"key":"3258_CR61","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41423-020-00555-x","volume":"18","author":"J Wei","year":"2021","unstructured":"Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, Zhu J, Han W (2021) Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol 18:792\u2013804. https:\/\/doi.org\/10.1038\/s41423-020-00555-x","journal-title":"Cell Mol Immunol"},{"key":"3258_CR62","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/CCO.0000000000000703","volume":"33","author":"F Wu","year":"2021","unstructured":"Wu F, Wang L, Zhou C (2021) Lung cancer in China: current and prospect. Curr Opin Oncol 33:40\u201346. https:\/\/doi.org\/10.1097\/CCO.0000000000000703","journal-title":"Curr Opin Oncol"},{"key":"3258_CR63","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W (2022) Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 135:584\u2013590. https:\/\/doi.org\/10.1097\/CM9.0000000000002108","journal-title":"Chin Med J (Engl)"},{"key":"3258_CR64","doi-asserted-by":"publisher","first-page":"962256","DOI":"10.3389\/fpubh.2022.962256","volume":"10","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Qiu M, Huang W, Hu S, Tan C, Nan F, Jiang X, Wu D, Li M, Li Q, Qin C (2022) Global status of research on radiotherapy for rectal cancer: a bibliometric and visual analysis. Front Public Health 10:962256. https:\/\/doi.org\/10.3389\/fpubh.2022.962256","journal-title":"Front Public Health"},{"key":"3258_CR65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF, Zhang X (2017) Engineering CAR-T cells. Biomark Res 5:22. https:\/\/doi.org\/10.1186\/s40364-017-0102-y","journal-title":"Biomark Res"},{"key":"3258_CR66","doi-asserted-by":"publisher","first-page":"969196","DOI":"10.3389\/fimmu.2022.969196","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang J, Chen P, Miao L (2022) A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022. Front Immunol 13:969196. https:\/\/doi.org\/10.3389\/fimmu.2022.969196","journal-title":"Front Immunol"},{"key":"3258_CR67","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y (2023) CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol 14:1101495. https:\/\/doi.org\/10.3389\/fimmu.2023.1101495","journal-title":"Front Immunol"},{"key":"3258_CR68","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","volume":"11","author":"J Zhao","year":"2018","unstructured":"Zhao J, Lin Q, Song Y, Liu D (2018) Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol 11:132. https:\/\/doi.org\/10.1186\/s13045-018-0677-2","journal-title":"J Hematol Oncol"},{"key":"3258_CR69","doi-asserted-by":"publisher","first-page":"797902","DOI":"10.3389\/fmolb.2021.797902","volume":"8","author":"D Zhong","year":"2021","unstructured":"Zhong D, Li Y, Huang Y, Hong X, Li J, Jin R (2021) Molecular mechanisms of exercise on cancer: a bibliometrics study and visualization analysis via CiteSpace. Front Mol Biosci 8:797902. https:\/\/doi.org\/10.3389\/fmolb.2021.797902","journal-title":"Front Mol Biosci"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03258-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03258-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03258-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T07:06:26Z","timestamp":1732172786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03258-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3258"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03258-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required for all analyses.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}